Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1530/ERC-20-0165 http://scihub22266oqcxt.onion/10.1530/ERC-20-0165 32508311!7546583!32508311     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32508311&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Endocr+Relat+Cancer 2020 ; 27 (9): R281-R292 Nephropedia Template TP {{tp|p=32508311|t=2020. COVID-19 and androgen-targeted therapy for prostate cancer patients |pdf=|usr=}}{{32508311}} gab.com Text COVID-19 and androgen-targeted therapy for prostate cancer patients JO: Endocr Relat Cancer http://www.kidney.de/pget.php?&tw=1&pmid=32508311 #FOAvip The current pandemic (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global health challenge with active development of antiviral drugs and vaccines seeking to reduce its significant disease burden. Early reports have confirmed that transmembrane serine protease 2 (TMPRSS2) and angiotensin converting enzyme 2 (ACE2) are critical targets of SARS-CoV-2 that facilitate viral entry into host cells. TMPRSS2 and ACE2 are expressed in multiple human tissues beyond the lung including the testes where predisposition to SARS-CoV-2 infection may exist. TMPRSS2 is an androgen-responsive gene and its fusion represents one of the most frequent alterations in prostate cancer. Androgen suppression by androgen deprivation therapy and androgen receptor signaling inhibitors form the foundation of prostate cancer treatment. In this review, we highlight the growing evidence in support of androgen regulation of TMPRSS2 and ACE2 and the potential clinical implications of using androgen suppression to downregulate TMPRSS2 to target SARS-CoV-2. We also discuss the future directions and controversies that need to be addressed in order to establish the viability of targeting TMPRSS2 and/or ACE2 through androgen signaling regulation for COVID-19 treatment, particularly its relevance in the context of prostate cancer management. Twit Text FOAVip COVID-19 and androgen-targeted therapy for prostate cancer patients ????Endocr Relat Cancer http://www.kidney.de/pget.php?&tw=1&pmid=32508311 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32508311 #FOAvip English Wikipedia <ref>{{Cite pmid|32508311}}</ref> COVID-19 and androgen-targeted therapy for prostate cancer patients #MMPMID32508311 Bhowmick NA; Oft J; Dorff T; Pal S; Agarwal N; Figlin RA; Posadas EM; Freedland SJ; Gong J Endocr Relat Cancer 2020[Sep]; 27 (9): R281-R292 PMID32508311show ga The current pandemic (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global health challenge with active development of antiviral drugs and vaccines seeking to reduce its significant disease burden. Early reports have confirmed that transmembrane serine protease 2 (TMPRSS2) and angiotensin converting enzyme 2 (ACE2) are critical targets of SARS-CoV-2 that facilitate viral entry into host cells. TMPRSS2 and ACE2 are expressed in multiple human tissues beyond the lung including the testes where predisposition to SARS-CoV-2 infection may exist. TMPRSS2 is an androgen-responsive gene and its fusion represents one of the most frequent alterations in prostate cancer. Androgen suppression by androgen deprivation therapy and androgen receptor signaling inhibitors form the foundation of prostate cancer treatment. In this review, we highlight the growing evidence in support of androgen regulation of TMPRSS2 and ACE2 and the potential clinical implications of using androgen suppression to downregulate TMPRSS2 to target SARS-CoV-2. We also discuss the future directions and controversies that need to be addressed in order to establish the viability of targeting TMPRSS2 and/or ACE2 through androgen signaling regulation for COVID-19 treatment, particularly its relevance in the context of prostate cancer management. |*Betacoronavirus[MESH] |Androgen Antagonists/*therapeutic use[MESH] |Androgens/physiology[MESH] |Angiotensin-Converting Enzyme 2[MESH] |COVID-19[MESH] |Coronavirus Infections/drug therapy/*etiology[MESH] |Humans[MESH] |Hypothalamo-Hypophyseal System/physiology[MESH] |Male[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/physiology[MESH] |Pneumonia, Viral/drug therapy/*etiology[MESH] |Prostatic Neoplasms/*drug therapy[MESH] |SARS-CoV-2[MESH]COVID-19 and androgen-targeted therapy for prostate cancer patients (epmc).pdf DeepDyve Pubget Overpricing